newsfilter
← Latest News
Business Wire·

Ipsen: ESMO 2021: Cabometyx® Demonstrates Sustained 78% Reduction in Risk of Disease Progression or Death in People Living With Uncommon Form of Thyroid Cancer

Ipsen's submission for extension of indication for Cabometyx® (cabozantinib) based on data from the COSMIC-311 trial received validation from the European Medicines Agency in August 2021 Separate follow-up data presented at the European Society f